GlassScriptPhysician profile
Sofia De La Camara
NPI 1023572153
$3,831.47
in general payments reported to CMS, 2019-2025
23 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $238 · 2023: $861 · 2024: $525 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,213 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.47 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $958.66 | 2021-2025 | |
| Incyte Corporation | $419.66 | 2024-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $387.36 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $385.27 | 2022-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $378.48 | 2022-2025 | |
| Abbvie INC. | $334.24 | 2024-2025 | |
| Lilly USA, LLC | $190.00 | 2021-2025 | Ebglyss, Taltz |
| Dermavant Sciences, INC. | $175.73 | 2023-2024 | Vtama |
| Ucb, INC. | $123.92 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $121.68 | 2022-2025 | Winlevi, Absorica Ld |
| Journey Medical Corporation | $69.19 | 2022-2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $43.70 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $42.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $42.52 | 2021 | |
| Cipher Pharmaceuticals US LLC | $28.28 | 2025 | Natroba, Spinosad |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nobelpharma America, LLC | $20.50 | 2025 | |
| Leo Pharma INC. | $19.80 | 2025 | Adbry |
| Botanix Sb INC | $19.72 | 2025 | Sofdra |
| Janssen Biotech, INC. | $17.08 | 2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $16.98 | 2024 | Zoryve |
| Dermira, INC. | $15.68 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.24 | 2021 | |
| Organon LLC | $7.79 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia De La Camara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.